Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nrx Pharmaceuticals Inc (NRXP)

Nrx Pharmaceuticals Inc (NRXP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 75,789
  • Shares Outstanding, K 29,605
  • Annual Sales, $ 0 K
  • Annual Income, $ -25,130 K
  • EBIT $ -15 M
  • EBITDA $ -15 M
  • 60-Month Beta 1.91
  • Price/Sales 182.21
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 289.79% (+195.49%)
  • Historical Volatility 90.85%
  • IV Percentile 70%
  • IV Rank 40.70%
  • IV High 688.62% on 11/21/25
  • IV Low 16.06% on 09/08/25
  • Expected Move (DTE 19) 0.94 (36.52%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 747
  • Volume Avg (30-Day) 171
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 5,362
  • Open Int (30-Day) 5,915
  • Expected Range 1.63 to 3.50

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.08
  • Number of Estimates 2
  • High Estimate -0.06
  • Low Estimate -0.09
  • Prior Year -0.30
  • Growth Rate Est. (year over year) +73.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.96 +30.61%
on 12/16/25
2.58 -0.78%
on 12/26/25
+0.22 (+9.40%)
since 11/26/25
3-Month
1.96 +30.61%
on 12/16/25
3.84 -33.33%
on 10/07/25
-0.39 (-13.22%)
since 09/26/25
52-Week
1.41 +81.56%
on 12/27/24
6.01 -57.40%
on 01/13/25
+1.03 (+67.32%)
since 12/26/24

Most Recent Stories

More News
NRx Pharmaceuticals (NASDAQ: NRXP) Eliminates Balance Sheet Debt Through Anson Equity Conversion

NRx Pharmaceuticals (NASDAQ: NRXP) announced it has repaid the remaining $5.4 million of balance sheet debt owed to Anson Funds LLC through an equity conversion into common stock with no warrants or repricing...

NRXP : 2.56 (+4.92%)
NRx Pharmaceuticals (Nasdaq:NRXP) announces elimination of all balance sheet debt following equity conversion

Remaining $5.4 million debt was repaid through strategic equity conversion in common stock with no additional warrants or adjustment provisions Company anticipates that Dec 31 balance sheet will reflect...

NRXP : 2.56 (+4.92%)
NRx Pharmaceuticals (NASDAQ: NRXP) Amends IND to Advance NRX-101 With TMS for Depression Treatment

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, said it amended its Investigational New Drug filing for NRX-101 to include use of the drug in combination with Transcranial...

NRXP : 2.56 (+4.92%)
NRx Pharmaceuticals to discuss new NRX-101 pipeline indication for augmentation of Transcranial Magnetic Stimulation

As previously announced, low dose D-cycloserine has been associated with augmentation of the antidepressant and antisuicidal response achieved by Transcranial Magnetic Stimulation (TMS). NRx has amended...

NRXP : 2.56 (+4.92%)
NRx Pharmaceuticals (NASDAQ: NRXP) Announces FDA Receipt of ANDA for KETAFREE With July 2026 Review Goal Date

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, said the FDA has received its Abbreviated New Drug Application for KETAFREE(TM), a preservative-free intravenous ketamine...

NRXP : 2.56 (+4.92%)
NRx Pharmaceuticals Announces US Food and Drug Administration (FDA) Receipt of ANDA for KETAFREE™, a Preservative-Free IV Ketamine

FDA has determined that NRx’s Abbreviated New Drug Application (ANDA) is “substantially complete” and received for review. Assigned GDUFA goal date is July 29, 2026. NRx has applied to FDA for use...

NRXP : 2.56 (+4.92%)
NRx Pharmaceuticals (NASDAQ: NRXP) and HOPE Therapeutics to Host Corporate Update Call

WILMINGTON, Del., Dec. 02, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it...

NRXP : 2.56 (+4.92%)
NRx Pharmaceuticals (NASDAQ: NRXP) to Present at NobleCon21

NRx Pharmaceuticals (NASDAQ: NRXP) Founder, Chairman and CEO Jonathan Javitt, M.D., M.P.H., will present at NobleCon21 on Dec. 3 at 4:30 p.m. EST, offering an update on the company’s expanded focus in...

NRXP : 2.56 (+4.92%)
NRx Pharmaceuticals (NASDAQ:NRXP) and HOPE Therapeutics to Present at NobleCon21 - Noble Capital Markets’ Twenty First Annual Emerging Growth Equity Conference

WILMINGTON, Del., Dec. 01, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, the “Company”, “NRx”), a clinical-stage biopharmaceutical company and HOPE Therapeutics, an interventional...

NRXP : 2.56 (+4.92%)
New to The Street Show #702 Airs Today on Bloomberg at 6:30 PM EST

The show airs as sponsored programming with TV commercials by Synergy CHC, Sustainable Green Team, Laser Pharmaceuticals, and PetVivo.

RDZN : 2.05 (unch)
ACXP : 3.19 (-7.80%)
NRXP : 2.56 (+4.92%)
AERT : 0.5351 (-0.45%)
CISO : 0.4402 (-3.68%)

Business Summary

NRX Pharmaceuticals Inc. is a patient-focused, clinical stage pharmaceutical company. It creates therapies to treat diseases where no medicines currently exist. NRX Pharmaceuticals Inc., formerly known as Big Rock Partners Acquisition Corp., is based in RADNOR, Pa.

See More

Key Turning Points

3rd Resistance Point 2.81
2nd Resistance Point 2.69
1st Resistance Point 2.63
Last Price 2.56
1st Support Level 2.45
2nd Support Level 2.33
3rd Support Level 2.27

See More

52-Week High 6.01
Fibonacci 61.8% 4.25
Fibonacci 50% 3.71
Fibonacci 38.2% 3.17
Last Price 2.56
52-Week Low 1.41

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar